A Preview Of Travere Therapeutics's Earnings

Travere Therapeutics (NASDAQ:TVTX) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Travere Therapeutics will report an earnings per share (EPS) of $-0.70.

Investors in Travere Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Performance in Previous Earnings

In the previous earnings release, the company beat EPS by $0.21, leading to a 2.6% drop in the share price the following trading session.

Here's a look at Travere Therapeutics's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

-0.86

-0.99

-1.26

EPS Actual

-0.65

-1.51

-0.94

2.27

Price Change %

-3.0%

3.0%

-6.0%

-12.0%

Analyst Observations about Travere Therapeutics

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Travere Therapeutics.

Analysts have provided Travere Therapeutics with 24 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $22.17, suggesting a potential 20.69% upside.

Comparing Ratings with Peers

The following analysis focuses on the analyst ratings and average 1-year price targets of Ardelyx, CareDx and Dynavax Technologies, three prominent industry players, ...